Long-Term Prophylaxis Cost-Effective for Von Willebrand Disease
Researchers sought to determine whether long-term prophylaxis against bleeds in patients with von Willebrand disease would be cost effective.
Researchers sought to determine whether long-term prophylaxis against bleeds in patients with von Willebrand disease would be cost effective.
Researchers sought to determine whether plasma-derived VWF would be effective in treating hemorrhage in young children with severe VWD.
Results showed the median ABR for all bleeds was reduced by 54.7%.
Researchers described a case study that suggested ibrutinib may have beneficial effects in patients with acquired von Willebrand syndrome that is secondary to Waldenström macroglobulinemia.
Researchers sought to determine whether the HemosIL VWF activity assay would be an effective method for identifying VWD.
Researchers sought to determine whether von Willebrand factor may be a potential target for therapies to address thrombotic complications in patients with COVID-19.
Researchers sought to define bleeding patterns and other characteristics in infants and toddlers with von Willebrand disease.
Researchers sought to determine whether recombinant VWF would be effective in reducing spontaneous bleeding for patients with severe VWD previously treated in an on-demand manner.
Acquired hemophilia A (AHA) and acquired von Willebrand syndrome (aVWS) are rare, life-threatening bleeding disorders that occur in patients with no bleeding history and no family history of a bleeding disorder.
Researchers sought to determine whether BT200, a new anti-von Willebrand factor, would have efficacy in patients with von Willebrand disease.